Logo image of MBX

MBX BIOSCIENCES INC (MBX) Stock Fundamental Analysis

USA - NASDAQ:MBX - US55287L1017 - Common Stock

19.365 USD
+1.4 (+7.82%)
Last: 10/29/2025, 3:24:10 PM
Fundamental Rating

3

Taking everything into account, MBX scores 3 out of 10 in our fundamental rating. MBX was compared to 192 industry peers in the Pharmaceuticals industry. MBX has a great financial health rating, but its profitability evaluates not so good. MBX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MBX has reported negative net income.
MBX had a negative operating cash flow in the past year.
MBX Yearly Net Income VS EBIT VS OCF VS FCFMBX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -33.27%, MBX perfoms like the industry average, outperforming 49.48% of the companies in the same industry.
MBX's Return On Equity of -35.13% is in line compared to the rest of the industry. MBX outperforms 58.33% of its industry peers.
Industry RankSector Rank
ROA -33.27%
ROE -35.13%
ROIC N/A
ROA(3y)-39.9%
ROA(5y)N/A
ROE(3y)-42.71%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MBX Yearly ROA, ROE, ROICMBX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -20 -40 -60

1.3 Margins

MBX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MBX Yearly Profit, Operating, Gross MarginsMBX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

MBX has more shares outstanding than it did 1 year ago.
MBX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MBX Yearly Shares OutstandingMBX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M
MBX Yearly Total Debt VS Total AssetsMBX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 38.02 indicates that MBX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 38.02, MBX belongs to the top of the industry, outperforming 96.35% of the companies in the same industry.
MBX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 38.02
ROIC/WACCN/A
WACCN/A
MBX Yearly LT Debt VS Equity VS FCFMBX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 19.50 indicates that MBX has no problem at all paying its short term obligations.
With an excellent Current ratio value of 19.50, MBX belongs to the best of the industry, outperforming 90.10% of the companies in the same industry.
A Quick Ratio of 19.50 indicates that MBX has no problem at all paying its short term obligations.
MBX has a better Quick ratio (19.50) than 90.10% of its industry peers.
Industry RankSector Rank
Current Ratio 19.5
Quick Ratio 19.5
MBX Yearly Current Assets VS Current LiabilitesMBX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for MBX have decreased strongly by -470.40% in the last year.
EPS 1Y (TTM)-470.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 19.45% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y76.18%
EPS Next 2Y32.62%
EPS Next 3Y19.45%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MBX Yearly EPS VS EstimatesMBX Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MBX. In the last year negative earnings were reported.
Also next year MBX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MBX Price Earnings VS Forward Price EarningsMBX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MBX Per share dataMBX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as MBX's earnings are expected to grow with 19.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.62%
EPS Next 3Y19.45%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MBX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MBX BIOSCIENCES INC

NASDAQ:MBX (10/29/2025, 3:24:10 PM)

19.365

+1.4 (+7.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-06 2025-11-06
Inst Owners80.04%
Inst Owner Change0%
Ins Owners3.1%
Ins Owner Change0%
Market Cap865.62M
Revenue(TTM)N/A
Net Income(TTM)-77019000
Analysts87.27
Price Target57.12 (194.97%)
Short Float %11.35%
Short Ratio2.79
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.56%
Min EPS beat(2)8.71%
Max EPS beat(2)24.42%
EPS beat(4)3
Avg EPS beat(4)12.66%
Min EPS beat(4)-1.32%
Max EPS beat(4)24.42%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)48.48%
PT rev (3m)49.33%
EPS NQ rev (1m)1.13%
EPS NQ rev (3m)-0.87%
EPS NY rev (1m)1.23%
EPS NY rev (3m)-0.95%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.95
P/tB 3.95
EV/EBITDA N/A
EPS(TTM)-4.54
EYN/A
EPS(NY)-2.79
Fwd EYN/A
FCF(TTM)-1.6
FCFYN/A
OCF(TTM)-1.58
OCFYN/A
SpS0
BVpS4.9
TBVpS4.9
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -33.27%
ROE -35.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.9%
ROA(5y)N/A
ROE(3y)-42.71%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 326.94%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.5
Quick Ratio 19.5
Altman-Z 38.02
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)409.29%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-470.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.08%
EPS Next Y76.18%
EPS Next 2Y32.62%
EPS Next 3Y19.45%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-93.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-55.64%
EBIT Next 3Y-28.78%
EBIT Next 5YN/A
FCF growth 1Y-73.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-71%
OCF growth 3YN/A
OCF growth 5YN/A

MBX BIOSCIENCES INC / MBX FAQ

What is the ChartMill fundamental rating of MBX BIOSCIENCES INC (MBX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MBX.


Can you provide the valuation status for MBX BIOSCIENCES INC?

ChartMill assigns a valuation rating of 0 / 10 to MBX BIOSCIENCES INC (MBX). This can be considered as Overvalued.


What is the profitability of MBX stock?

MBX BIOSCIENCES INC (MBX) has a profitability rating of 1 / 10.


What is the earnings growth outlook for MBX BIOSCIENCES INC?

The Earnings per Share (EPS) of MBX BIOSCIENCES INC (MBX) is expected to grow by 76.18% in the next year.